WO2001010427A2 - Use of anti-muscarinic agents for treating skin disorders - Google Patents
Use of anti-muscarinic agents for treating skin disorders Download PDFInfo
- Publication number
- WO2001010427A2 WO2001010427A2 PCT/GB2000/003032 GB0003032W WO0110427A2 WO 2001010427 A2 WO2001010427 A2 WO 2001010427A2 GB 0003032 W GB0003032 W GB 0003032W WO 0110427 A2 WO0110427 A2 WO 0110427A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- use according
- compound
- glycopyrrolate
- condition
- tiotropium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the treatment of topical conditions using anti-muscarinic agents.
- Gajewski Pol. Tyg. Lek.25(47) 1815-6 (1970), discloses that psoriatic skin rashes disappeared in the course of atropine therapy.
- quaternary ammonium atropine-like drugs have been used in the treatment of hyperhydrosis, i.e. excessive sweating. They inhibit sweating but generally do not have systemic effects.
- US-A-5185350 discloses substituted pyridinyl amines that are useful as topical anti-inflammatory agents for the treatment of various dermatoses.
- US-A-5084281 discloses the use of cholinergic agents, in combination with a solution of sea water or a sea salt solution, for the treatment of persistent, neuropathic dermal ulcers.
- WO-A-94/15623 discloses pharmaceutical compositions comprising various components, including urea and hyaurolonic acid, for the treatment of contact dermatitis and other topical conditions.
- WO- A-98/00119 discloses the use of agents that affect non-neuronal acetylcholine functions, for the treatment of skin ailments. It also discloses that topically effective antagonists of muscarinic receptors, including ipratropium, are useful for the treatment of skin ailments.
- Various skin ailments that are disclosed include atopic dermatitis, neurodermatitis, psoriasis and cholinergic urticaria.
- Summary of the Invention According to the present invention, skin conditions are treated by the topical application of a quaternary ammonium or other compound having anti-muscarinic activity, a high dipole moment (greater than 4D) and high anti-proliferation activity (at least 50% inhibition at 10 ⁇ M). It may also have high receptor-binding activity (half-life for receptor dissociation greater than 0.11 h at Ml). Topical compositions containing such compounds may also be new. Description of the Invention
- This invention is based at least in part on studies, using the assay described below, showing the inhibition of keratinocyte proliferation using anti-muscarinic agents.
- agents may be defined by their dipole moment. Dipole moment is related to drug polarity, which in turn is related to the penetration of a given drug through the upper layers of skin tissue.
- J. Pharm. Sci. (1984) 73(4):461-467 demonstrated a linear relationship between drug flux across the stratum corneum and dipole moment, and that drugs with a dipole moment of greater than 4.0 show limited systemic exposure due to poor passage across the skin to the circulatory system.
- Atropine (1.232D), and homatropine ( 1.066D) may be effective in the given assay, for the inhibition of proliferation, but have central nervous activity when applied topically. While this in some indications may be an attractive property (e.g. motion sickness), for local conditions in which the drug is applied topically, it can give rise to serious side effects that limit the use of the drug.
- Other anti-muscarinic agents also show efficacy in the proliferation assay. These agents may be characterised by dipole moments greater than that of atropine, e.g. scopolamine (3.946D), revatropate (4.168D), ipratropium (13.45D) and glycopyrrolate (15.10D).
- Agents with a high dipole moment are more suitable for topical administration to treat skin conditions.
- This invention therefore relates to the use of anti-muscarinic agents for the treatment of skin conditions, especially psoriasis, in which there is a low potential for systemic exposure as defined by a dipole moment greater than 4.0D, and preferably greater than 10D.
- suitable antiproliferative anti-muscarinic agents have a human plasma half-life of less than 3 hours.
- Systemic pharmacological effects characteristic of anti-muscarinic agents are caused by high sustained levels of drug in the plasma. This leads to distribution of the compound to receptors around the body.
- a combination of antiproliferative activity (for efficacy) and low plasma half-life (to limit side effects) is necessary.
- Such compounds of short plasma half-life include, but are not limited to, glycopyrrolate, ipratropium and tiotropium.
- Agents for use in this invention preferably also have high receptor-binding affinity.
- a long duration of action is extremely desirable for a topically applied drug to treat local conditions. This leads to low reapplication rates of medication, which in turn ensures minimum disturbance to patient lifestyle, and high patient compliance.
- Compounds with high receptor binding affinity include glycopyrrolate, ipratropium and tiotropium.
- ipratropium meets the criteria described above, it is not as satisfactory as a treatment of skin conditions when compared to glycopyrrolate and tiotropium. This is not due to its receptor affinity (which is similar to that of glycopyrrolate) but is due to its high off rate of receptor binding. Both glycopyrrolate and tiotropium have receptor off rates that are very attractive for dermal dosing. Barnes, British Journal of Pharmacology (1999) 127:413-420, showed a t Vi off set for glycopyrrolate of 96minutes compared to 59min for ipratropium in a clinical study of muscarinic activity in human smooth muscle.
- glycopyrrolate is known to have a longer duration of action in muscarinic antagonism than ipratropium; see J. Allergy Clin. Immunol. (1988) 82:115.
- a two day duration of action from a single dermal application appears to be common, in the use of glycopyrrolate.
- suitable agents for use in the invention may initially be identified by the Assay Protocol described below. This is a model of psoriasis and thus of a proliferative skin condition.
- An agent for use in the invention preferably has an IC 50 value below 100 ⁇ M, most preferably below 10 ⁇ M, e.g. below 1 ⁇ M, and most preferably below 100 nM.
- agents that can be used in the invention, provided that they meet the essential criteria, include ambutonium, benzilonium, dibutoline, diphemanil, emepronium, glycopyrrolate, isopropamide, lachesine, mepenzolate, methantheline, oxyphenonium, oxytroprium, penthienate, phenthimentonium, pipenzolate, poldine, tiemonium, tiotropium, tricyclamol and tridihexethyl. Glycopyrrolate is preferred.
- These and other compounds for use in the invention may be provided in the form of a free base or salt. All such forms are within the scope of the invention, and in particular salts, organic and inorganic, are included. For example, quaternary ammonium compounds may be provided as a halide or other salt.
- Many anti-muscarinic agents exhibit isomerism, whether optical or structural elements
- compositions include, but are not limited to, creams, ointments, gels, shampoos, lotions, ionotophoresis, patches and emollients.
- This invention also includes the use of anti-muscarinic agents to treat skin condition by topical administration, in which the drug is placed in a formulation system in which the drug flux across the skin is maintained at such a rate that systemic blood levels are retained at a low level. However, the drug flux is maintained at a level to effect topical activity in the skin. In this way, anti- muscarinic agents may be used that would otherwise be limited by their side-effects.
- Conditions that may be treated include all forms of psoriasis, including psoriatic and scalp arthritis, skin cancer, melanoma, pemphigus, atopic dermatitis, neuro-dermatitis, eczema, contact dermatitis, acne, leprosy, seborrheic dermatitis, lupus and urticaria.
- the invention is particularly suited to the treatment of topical proliferative conditions such as psoriasis.
- Treatment may be combined with radiological therapy.
- treatment maybe combined with a conventional agent, of which examples include steroids, vitamins A, D and their analogues, salicylates, anthralines and coal tar preparations.
- the amount of the active agent to be used will depend on the usual factors, such as the potency of the agent, the nature and state of the condition to be treated, the state of the patient, etc. All these factors can be taken into account, and the relevant dose determined accordingly, by the skilled man.
- Neo-natal human epithelial keratinocytes (Biowhittaker) are grown in defined media (Keratinocvte growth medium KGM-2, Biowhittaker) until confluent. Passages 2-4 are preferred. Cells are plated in a 96-well plate at a density of 1 x 10 4 / well in lOO ⁇ l KGM-2. Cells are left to settle at 37°C for 48 hours. Medium is removed and drug is added. Vitamin D3 is included as a standard, and a dose-response to the drug is performed. Cell proliferation is measured 5 days (or 3 days in the case of ipratropium) after addition of drug.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00949799A EP1202723A2 (en) | 1999-08-09 | 2000-08-07 | Use of anti-muscarinic agents for treating skin disorders |
IL14789100A IL147891A0 (en) | 1999-08-09 | 2000-08-07 | Topical use of anti-muscarnic agents |
CA002378445A CA2378445A1 (en) | 1999-08-09 | 2000-08-07 | Use of anti-muscarinic agents for treating skin disorders |
AU63064/00A AU6306400A (en) | 1999-08-09 | 2000-08-07 | Topical use of anti-muscarinic agents |
JP2001514947A JP2003506405A (en) | 1999-08-09 | 2000-08-07 | Topical use of antimuscarinics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9918760.1A GB9918760D0 (en) | 1999-08-09 | 1999-08-09 | Topical treatment |
GB9918760.1 | 1999-08-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001010427A2 true WO2001010427A2 (en) | 2001-02-15 |
WO2001010427A3 WO2001010427A3 (en) | 2001-09-20 |
Family
ID=10858850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/003032 WO2001010427A2 (en) | 1999-08-09 | 2000-08-07 | Use of anti-muscarinic agents for treating skin disorders |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1202723A2 (en) |
JP (1) | JP2003506405A (en) |
AU (1) | AU6306400A (en) |
CA (1) | CA2378445A1 (en) |
GB (1) | GB9918760D0 (en) |
IL (1) | IL147891A0 (en) |
WO (1) | WO2001010427A2 (en) |
ZA (1) | ZA200200795B (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072095A2 (en) * | 2001-03-13 | 2002-09-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium salts for treating inflammatory diseases |
WO2006054312A1 (en) * | 2004-11-16 | 2006-05-26 | Munisekhar Medasani | Ammonium compounds for treating psoriasis and eczema |
WO2007141530A2 (en) * | 2006-06-07 | 2007-12-13 | Summit (Cambridge) Limited | Treatment of excess sebum production |
US7504432B2 (en) * | 2000-07-11 | 2009-03-17 | Banyu Pharmaceutical Co., Ltd. | Ester derivatives |
WO2009068876A1 (en) * | 2007-11-30 | 2009-06-04 | Summit Corporation Plc | Compositions for the treatment of skin disorders |
WO2009150408A2 (en) * | 2008-06-13 | 2009-12-17 | Summit Corporation Plc | Topical antimuscarinic formulations |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
US9006461B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
WO2016173817A1 (en) | 2015-04-28 | 2016-11-03 | Unilever Plc | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same |
US9610278B2 (en) | 2013-02-28 | 2017-04-04 | Dermira, Inc. | Glycopyrrolate salts |
US10307355B2 (en) | 2015-04-28 | 2019-06-04 | Conopco, Inc. | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same |
CN110898227A (en) * | 2019-11-04 | 2020-03-24 | 上海交通大学医学院附属瑞金医院卢湾分院 | Combined medicine for treating psoriasis and application thereof |
CN112730821A (en) * | 2019-10-14 | 2021-04-30 | 泰州医药城国科化物生物医药科技有限公司 | Method for analyzing long-acting property of receptor antagonist |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004016179A1 (en) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Compounds for the treatment of proliferative processes |
ES2389231T3 (en) * | 2005-12-21 | 2012-10-24 | Meda Pharma Gmbh & Co. Kg | Combination of anticholinergics, glucocorticoids and beta2 agonists for the treatment of inflammatory diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19626373A1 (en) * | 1996-07-02 | 1998-01-08 | Boehringer Ingelheim Kg | Novel use of active ingredients that affect the function of non-neuronal acetylcholine |
WO1999059577A1 (en) * | 1998-05-21 | 1999-11-25 | El Khoury George F | Topical application of muscarinic analgesic drugs such as neostigmine |
-
1999
- 1999-08-09 GB GBGB9918760.1A patent/GB9918760D0/en not_active Ceased
-
2000
- 2000-08-07 AU AU63064/00A patent/AU6306400A/en not_active Abandoned
- 2000-08-07 CA CA002378445A patent/CA2378445A1/en not_active Abandoned
- 2000-08-07 JP JP2001514947A patent/JP2003506405A/en active Pending
- 2000-08-07 EP EP00949799A patent/EP1202723A2/en not_active Withdrawn
- 2000-08-07 WO PCT/GB2000/003032 patent/WO2001010427A2/en not_active Application Discontinuation
- 2000-08-07 IL IL14789100A patent/IL147891A0/en unknown
-
2002
- 2002-01-29 ZA ZA200200795A patent/ZA200200795B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19626373A1 (en) * | 1996-07-02 | 1998-01-08 | Boehringer Ingelheim Kg | Novel use of active ingredients that affect the function of non-neuronal acetylcholine |
WO1999059577A1 (en) * | 1998-05-21 | 1999-11-25 | El Khoury George F | Topical application of muscarinic analgesic drugs such as neostigmine |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7504432B2 (en) * | 2000-07-11 | 2009-03-17 | Banyu Pharmaceutical Co., Ltd. | Ester derivatives |
WO2002072095A2 (en) * | 2001-03-13 | 2002-09-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium salts for treating inflammatory diseases |
WO2002072095A3 (en) * | 2001-03-13 | 2003-11-27 | Boehringer Ingelheim Pharma | Tiotropium salts for treating inflammatory diseases |
US7994188B2 (en) | 2001-03-13 | 2011-08-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Compounds for treating inflammatory diseases |
WO2006054312A1 (en) * | 2004-11-16 | 2006-05-26 | Munisekhar Medasani | Ammonium compounds for treating psoriasis and eczema |
WO2007141530A2 (en) * | 2006-06-07 | 2007-12-13 | Summit (Cambridge) Limited | Treatment of excess sebum production |
WO2007141530A3 (en) * | 2006-06-07 | 2008-06-05 | Daniolabs Ltd | Treatment of excess sebum production |
WO2009068876A1 (en) * | 2007-11-30 | 2009-06-04 | Summit Corporation Plc | Compositions for the treatment of skin disorders |
WO2009150408A2 (en) * | 2008-06-13 | 2009-12-17 | Summit Corporation Plc | Topical antimuscarinic formulations |
WO2009150408A3 (en) * | 2008-06-13 | 2010-05-06 | Summit Corporation Plc | Topical antimuscarinic formulations |
US9259414B2 (en) | 2013-02-28 | 2016-02-16 | Dermira, Inc. | Glycopyrrolate salts |
US10548875B2 (en) | 2013-02-28 | 2020-02-04 | Dermira, Inc. | Glycopyrrolate salts |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
US11291651B2 (en) | 2013-02-28 | 2022-04-05 | Journey Medical Corporation | Glycopyrrolate salts |
US9610278B2 (en) | 2013-02-28 | 2017-04-04 | Dermira, Inc. | Glycopyrrolate salts |
US10004717B2 (en) | 2013-02-28 | 2018-06-26 | Dermira, Inc. | Glycopyrrolate salts |
US11291652B2 (en) | 2013-02-28 | 2022-04-05 | Journey Medical Corporation | Glycopyrrolate salts |
US9006461B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
US10543192B2 (en) | 2013-02-28 | 2020-01-28 | Dermira, Inc. | Glycopyrrolate salts |
US10307355B2 (en) | 2015-04-28 | 2019-06-04 | Conopco, Inc. | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same |
US10155733B2 (en) | 2015-04-28 | 2018-12-18 | Conopco, Inc. | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same |
WO2016173817A1 (en) | 2015-04-28 | 2016-11-03 | Unilever Plc | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same |
CN112730821A (en) * | 2019-10-14 | 2021-04-30 | 泰州医药城国科化物生物医药科技有限公司 | Method for analyzing long-acting property of receptor antagonist |
CN112730821B (en) * | 2019-10-14 | 2024-04-09 | 泰州医药城国科化物生物医药科技有限公司 | Method for analyzing long-acting property of receptor antagonist |
CN110898227A (en) * | 2019-11-04 | 2020-03-24 | 上海交通大学医学院附属瑞金医院卢湾分院 | Combined medicine for treating psoriasis and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2378445A1 (en) | 2001-02-15 |
AU6306400A (en) | 2001-03-05 |
WO2001010427A3 (en) | 2001-09-20 |
GB9918760D0 (en) | 1999-10-13 |
IL147891A0 (en) | 2002-08-14 |
ZA200200795B (en) | 2003-03-26 |
EP1202723A2 (en) | 2002-05-08 |
JP2003506405A (en) | 2003-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4661524A (en) | Topical treatment and composition | |
WO2001010427A2 (en) | Use of anti-muscarinic agents for treating skin disorders | |
US6238683B1 (en) | Anhydrous topical skin preparations | |
EP0954278B1 (en) | Pharmaceutical compositions containing kukui nut oil | |
US6841161B1 (en) | Topical compositions | |
EP1281398B1 (en) | Dermal compositions containing coenzyme q as the active ingredient | |
CN102341105A (en) | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications | |
EP0506658B1 (en) | Compositions and method for treating painful, inflammatory or allergic disorders | |
AU2018221880B2 (en) | Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases | |
JP2015096506A (en) | Compositions for prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof | |
EP3182955B1 (en) | Compositions and methods for controlled moisturizing and release of active ingredients | |
KR20000075572A (en) | Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo | |
DE4328217C2 (en) | Therapeutic system for the treatment of psoriasis | |
KR20010021851A (en) | Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith | |
EP0535237A1 (en) | Composition for relieving skin irritation and external preparation for percutaneous adminstration containing the same | |
CN106061497A (en) | Methods and compositions for treatment of peripheral neuropathies | |
MXPA02001351A (en) | Topical use of anti-muscarinic agents | |
EP1148883B1 (en) | Use of tricyclic antidepressants for treatment of headache | |
WO2007086582A1 (en) | OIL-IN-WATER TYPE EMULSION LOTION CONTAINING 22-OXA-1α,25-DIHYDROXYVITAMIN D3 AND METHOD OF TREATING SKIN DISEASE BY USING THE SAME | |
KR20000029523A (en) | Formulation for the treatment and/or prophylaxis of dementia | |
US20220273671A1 (en) | Topical formulations for treatment of peripheral neuropathies | |
Katari et al. | Prilocaine: Mechanisms and application | |
CN114786651A (en) | Preparation | |
CA3085974A1 (en) | Semi-solid dosage form for topical application | |
CA2345501A1 (en) | Anhydrous topical skin preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000949799 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/00795 Country of ref document: ZA Ref document number: 147891 Country of ref document: IL Ref document number: 200200795 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2378445 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/001351 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 63064/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10048744 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000949799 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000949799 Country of ref document: EP |